Literature DB >> 19327430

Usefulness of peak exercise oxygen consumption and the heart failure survival score to predict survival in patients >65 years of age with heart failure.

Mona N Parikh1, Lars H Lund, Ayumi Goda, Donna Mancini.   

Abstract

Peak exercise oxygen consumption (Vo(2)) and the Heart Failure (HF) Survival Score (HFSS) were developed in middle-aged patient cohorts referred for heart transplantation with HF. The prognostic value of Vo(2) in patients >65 years has not been well studied. Accordingly, the prognostic value of peak Vo(2) was evaluated in these patients with HF. A retrospective analysis of 396 patients with HF >65 years with cardiopulmonary exercise testing was performed. Peak Vo(2) and components of the HFSS (presence of coronary artery disease, left ventricular ejection fraction, heart rate, mean arterial blood pressure, presence of intraventricular conduction defects, and serum sodium) were collected. Follow-up averaged 1,038 +/- 983 days. Outcome events were defined as death, implantation of a left ventricular assist device, or urgent transplantation. Patients were divided into risk strata for peak Vo(2) and HFSS based on previous cut-off points. Survival curves were derived using Kaplan-Meier analysis and compared using log-rank analysis. Survival differed markedly by Vo(2) stratum (p <0.0001), with significantly better survival rates for the low- (>14 ml/kg/min) versus medium- (10 to 14 ml/kg/min), low- versus high- (<10 ml/kg/min), and medium- versus high-risk strata (all p <0.05). Survival also differed markedly by HFSS stratum (p <0.0001), with significantly better survival rates for the low- (> or =8.10) versus medium- (7.20 to 8.09), low- versus high- (< or =7.19), and medium- versus high-risk strata (all p <0.0001). In conclusion, peak Vo(2) and the HFSS were both excellent parameters to predict survival in patients >65 years with HF.

Entities:  

Mesh:

Year:  2009        PMID: 19327430     DOI: 10.1016/j.amjcard.2008.12.010

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?

Authors:  Barbara S Doumouras; Douglas S Lee; Wayne C Levy; Ana C Alba
Journal:  Curr Heart Fail Rep       Date:  2018-02

2.  Response to letter to the editor by Dr. Vitor Oliveira Carvalho and Guilherme Veiga Guimaraes: Is the 6-min walking test a submaximal exercise test in heart failure patients?

Authors:  Melissa L Jehn; Arno Schmidt Trucksäss
Journal:  Eur J Appl Physiol       Date:  2009-10-16       Impact factor: 3.078

Review 3.  A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure.

Authors:  Lawrence P Cahalin; Paul Chase; Ross Arena; Jonathan Myers; Daniel Bensimhon; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman; Sherry Pinkstaff; Carl J Lavie; Marco Guazzi
Journal:  Heart Fail Rev       Date:  2013-01       Impact factor: 4.214

4.  Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score.

Authors:  Jennifer Franke; Andreas Lindmark; Matthias Hochadel; Christian Zugck; Eva Koerner; Jeannette Keppler; Philipp Ehlermann; Ralph Winkler; Ralf Zahn; Hugo A Katus; Jochen Senges; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2014-11-06       Impact factor: 5.460

Review 5.  Evaluation of a Heart Transplant Candidate.

Authors:  Sook Jin Lee; Kyung Hee Kim; Suk Keun Hong; Shelley Hankins
Journal:  Curr Cardiol Rep       Date:  2017-11-04       Impact factor: 2.931

6.  Global Longitudinal Strain Predicts Poor Functional Capacity in Patients with Systolic Heart Failure.

Authors:  Rafael José Coelho Maia; Simone Cristina Soares Brandão; Jéssica Leite; Giordano Bruno Parente; Filipe Pinheiro; Bruna Thays Santana Araújo; Maria Inês Remígio Aguiar; Sílvia Marinho Martins; Daniella Cunha Brandão; Armele Dornelas de Andrade
Journal:  Arq Bras Cardiol       Date:  2019-07-18       Impact factor: 2.000

Review 7.  Heart failure with mid-range or mildly reduced ejection fraction.

Authors:  Gianluigi Savarese; Davide Stolfo; Gianfranco Sinagra; Lars H Lund
Journal:  Nat Rev Cardiol       Date:  2021-09-06       Impact factor: 32.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.